Avadel Pharmaceuticals is deeply undervalued, with LUMRYZ and Valiloxybate offering $2B+ peak sales potential in sleep disorders. AVDL's once-at-bedtime Oxybate franchise is clinically superior, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback